PTAB Shuts Down Challenge To Gilead's Hep C Drug Patents

Law360 (June 13, 2018, 8:05 PM EDT) -- The Patent Trial and Appeal Board on Wednesday shot down the last of eight related requests filed by a nonprofit group focused on drug competition to review Gilead Pharmasset LLC's patents covering its series of blockbuster hepatitis C medications.

The PTAB started issuing its rejections of the Initiative for Medicines, Access & Knowledge Inc.'s petitions in early May, culminating in its final two Wednesday. The board said I-MAK failed to prove that any of the six patents at issue could be invalidated based on the prior art listed in the petitions.

Wednesday's order closes out a set of petitions I-MAK filed in October....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!